Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

Pediatric Blood and Cancer

Volumn 61, Issue 9, 2014, Pages 1544-1550

  Reiss, Ulrike M ^a   Schwartz, Jeffrey ^b   Sakamoto, Kathleen M ^c,g   Puthenveetil, Geetha ^d   Ogawa, Masayo ^e   Bedrosian, Camille L ^e   Ware, Russell E ^a,f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Children's Clinic   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^e ALEXION PHARMACEUTICALS   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Complement inhibition; Eculizumab; Paroxysmal nocturnal hemoglobinuria; Phase I II

Indexed keywords

COMPLEMENT; ECULIZUMAB; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT INHIBITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPOTENSION; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; TREATMENT DURATION; UPPER ABDOMINAL PAIN;

CHILDREN; COMPLEMENT INHIBITION; ECULIZUMAB; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE I/II;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SAFETY; TISSUE DISTRIBUTION;

EID: 84904438509     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25068     Document Type: Article

References (43)

1. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73:703-711.
2. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259:1318-1320.
3. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144:3478-3483.
4. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160:1558-1578.
5. Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293:1653-1662.
6. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121:4985-4996.
7. van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10:1-10.
8. Basara N, Antunovic P, Sefer D, et al. Megakaryocyte progenitors in paroxysmal nocturnal haemoglobinuria are sensitive to complement. Eur J Haematol 1996; 57:227-229.
9. Dessypris EN, Gleaton JH, Clark DA. Increased sensitivity to complement of megakaryocyte progenitors in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1988; 69:305-309.
10. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253-1258.
11. Socie G, Mary JY, de GA, et al. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348:573-577.
12. Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004; 83:193-207.
13. Moyo VM, Mukhina GL, Garrett ES, et al. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004; 126:133-138.
14. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699-3709.
15. Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol 2007; 35:523-533.
16. Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 1991; 325:991-996.
17. Naithani R, Mahapatra M, Dutta P, et al. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence-A retrospective analysis of 18 cases. Ind J Pediatr 2008; 75:575-578.
18. Curran KJ, Kernan NA, Prockop SE, et al. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer 2012; 59:525-529.
19. van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol 2005; 128:571-577.
20. Urbano-Ispizua A, Schrezenmeier H, Muus P, et al. Clinical characteristics of classic paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients: A comparison with classic PNH in adults. An International PNH registry study. Blood 2011; 118:2102.
21. Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 2012; 97:1666-1673.
22. Peffault de Latour R, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: Natural histroy of disease subcategories. Blood 2008; 3099-3106.
23. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33:1389-1401.
24. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111:1840-1847.
25. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:2559-2565.
26. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552-559.
27. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233-1243.
28. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110:4123-4128.
29. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010; 85:553-559.
30. Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162:62-73.
31. Kanakura Y, Ohyashiki K, Shichishima T, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol 2013; 98:406-416.
32. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood 2011; 117:6786-6792.
33. Mouksassi S, Kassir N, Marier J. Eculizumab weight-based dosing strategies in pediatric aHUS patients between neonates and 12 years of age and dosing strategies of eculizumab in pediatric aHUS patients undergoing plasma exchange-Abbreviated report. 6-22-2009 Pharsight.
34. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96:1564-1572.
35. Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS clinical trial. Int J Hematol 2011; 93:36-46.
36. Bauters T, Bordon V, Robays H, et al. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria. J Pediatr Hematol Oncol 2012; 34:e346-e348.
37. Yen TA, Lu MY, Kuo MF, et al. Eculizumab treatment of paroxysmal nocturnal hemoglobinuria presenting as moyamoya syndrome in a 9-year-old male. Pediatr Blood Cancer 2012; 59:203-204.
38. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009; 113:4094-4100.
39. Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010; 95:567-573.
40. Jasinski M, Pantazopoulos P, Rother RP, et al. A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins. Blood 2004; 103:2827-2834.
41. Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. New Engl J Med 2014; 370:632-639.
42. Matos-Fernandez NA, Abou Mourad YR, Caceres W, et al. Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 2009; 15:656-661.
43. Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999; 104:392-396.